Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Q1 2023 Results Earnings Conference Call April 28, 2023 4:30 PM ET
Company Participants
Matt Steinberg - Investor Relations, Lazar FINN Partners
Scott Davis - Chief Executive Officer
Jason Jones - Chief Operating Officer
Jerome Wong - Chief Financial Officer
Conference Call Participants
Swayampakula Ramakanth - H.C. Wainwright & Co.
Operator
Greetings, and welcome to the Ekso Bionics First Quarter 2023 Financial Results Conference Call.
At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions]. And as a reminder, this conference is being recorded.
It is now my pleasure to introduce your host, Matt Steinberg, FINN Partners. Thank you, sir. You may begin.
Matt Steinberg
Thank you, operator. And thank you all for participating in today's call. Joining me from Ekso Bionics are Scott Davis, Chief Executive Officer; Jerome Wong, Chief Financial Officer; and Jason Jones, Chief Operating Officer.
Today, Ekso Bionics released financial results for the quarter ended March 31, 2023. A copy of the press release is available on the company's website.
Before we begin, I'd like to remind you that management will make statements during this call that include forward-looking statements within the meaning of the federal securities laws, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements made during this call that are not statements of historical fact should be deemed to be forward-looking statements.
All forward-looking statements, including statements regarding our business strategy, future financial or operating expectations, or our expectations of the regulatory landscape governing our products and operations are based upon management's current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements.
Accordingly, you should not place undue reliance on these statements. For a list and description of the risks and uncertainties associated with our businesses, please see our filings with the Securities and Exchange Commission. Ekso disclaims any obligation, except as required by law, to update or revise any financial or operational projections, its regulatory outlook or other forward-looking statements, whether because of new information, future events or otherwise.
This conference call contains time sensitive information and is accurate only as of the broadcast today, April 27, 2023.
I will now turn the call over to Ekso Bionics' Chief Executive Officer, Scott Davis.